MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

V Woodcock, Mark Middleton, Christian Rolfo, Elena Elez, Sandra Van Schaeybroeck, Julien Taieb, Jennifer Houlden, Linda Collins, Sharon Love, C Roberts, Thierry Andre, Robert Jones, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, alberto Bardelli, Pierre Laurent=puig, gordon McGregor, Tim Maughan, Josef TaberneroMarc Peeters, Richard Wilson

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Original languageEnglish
Title of host publicationMErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
PublisherNational Cancer Research Institute
DOIs
Publication statusPublished - 11 Oct 2016

Cite this

Woodcock, V., Middleton, M., Rolfo, C., Elez, E., Van Schaeybroeck, S., Taieb, J., ... Wilson, R. (2016). MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. In MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours National Cancer Research Institute. https://doi.org/10.1093/annonc/mdw370.28
Woodcock, V ; Middleton, Mark ; Rolfo, Christian ; Elez, Elena ; Van Schaeybroeck, Sandra ; Taieb, Julien ; Houlden, Jennifer ; Collins, Linda ; Love, Sharon ; Roberts, C ; Andre, Thierry ; Jones, Robert ; Lawler, Mark ; Di Nicolantonio, Federica ; Grayson, Margaret ; Bardelli, alberto ; Laurent=puig, Pierre ; McGregor, gordon ; Maughan, Tim ; Tabernero, Josef ; Peeters, Marc ; Wilson, Richard. / MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute, 2016.
@inproceedings{30a2c2a1feae4d759d7912ddd52b43e5,
title = "MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours",
author = "V Woodcock and Mark Middleton and Christian Rolfo and Elena Elez and {Van Schaeybroeck}, Sandra and Julien Taieb and Jennifer Houlden and Linda Collins and Sharon Love and C Roberts and Thierry Andre and Robert Jones and Mark Lawler and {Di Nicolantonio}, Federica and Margaret Grayson and alberto Bardelli and Pierre Laurent=puig and gordon McGregor and Tim Maughan and Josef Tabernero and Marc Peeters and Richard Wilson",
year = "2016",
month = "10",
day = "11",
doi = "10.1093/annonc/mdw370.28",
language = "English",
booktitle = "MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours",
publisher = "National Cancer Research Institute",

}

Woodcock, V, Middleton, M, Rolfo, C, Elez, E, Van Schaeybroeck, S, Taieb, J, Houlden, J, Collins, L, Love, S, Roberts, C, Andre, T, Jones, R, Lawler, M, Di Nicolantonio, F, Grayson, M, Bardelli, A, Laurent=puig, P, McGregor, G, Maughan, T, Tabernero, J, Peeters, M & Wilson, R 2016, MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. in MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute. https://doi.org/10.1093/annonc/mdw370.28

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. / Woodcock, V; Middleton, Mark; Rolfo, Christian; Elez, Elena; Van Schaeybroeck, Sandra; Taieb, Julien; Houlden, Jennifer; Collins, Linda; Love, Sharon; Roberts, C; Andre, Thierry; Jones, Robert; Lawler, Mark; Di Nicolantonio, Federica; Grayson, Margaret; Bardelli, alberto; Laurent=puig, Pierre; McGregor, gordon; Maughan, Tim; Tabernero, Josef; Peeters, Marc; Wilson, Richard.

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute, 2016.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

AU - Woodcock, V

AU - Middleton, Mark

AU - Rolfo, Christian

AU - Elez, Elena

AU - Van Schaeybroeck, Sandra

AU - Taieb, Julien

AU - Houlden, Jennifer

AU - Collins, Linda

AU - Love, Sharon

AU - Roberts, C

AU - Andre, Thierry

AU - Jones, Robert

AU - Lawler, Mark

AU - Di Nicolantonio, Federica

AU - Grayson, Margaret

AU - Bardelli, alberto

AU - Laurent=puig, Pierre

AU - McGregor, gordon

AU - Maughan, Tim

AU - Tabernero, Josef

AU - Peeters, Marc

AU - Wilson, Richard

PY - 2016/10/11

Y1 - 2016/10/11

U2 - 10.1093/annonc/mdw370.28

DO - 10.1093/annonc/mdw370.28

M3 - Conference contribution

BT - MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

PB - National Cancer Research Institute

ER -

Woodcock V, Middleton M, Rolfo C, Elez E, Van Schaeybroeck S, Taieb J et al. MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. In MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute. 2016 https://doi.org/10.1093/annonc/mdw370.28